Clinical trial · Observational
Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer
NCT03214991CI-TRIAL-00031538unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to determine the usefulness of circulating tumor DNA as a prognostic factor in patients with pancreatic cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Overall survival rate
- timeFrame
- 48 months
- description
- Comparison of overall survival rates between patients with and without blood-circulating tumor DNA
Secondary outcomes (5)
- measure
- Overall survival rate according to the amount of blood circulating tumor DNA
- timeFrame
- 48mo
- description
- Overall survival rate according to the amount of blood circulating tumor DNA
- measure
- K-ras mutation
- timeFrame
- 48 months
- description
- The concordance rate of K-ras mutation in EUS-FNA specimen and K-ras mutation in blood circulating tumor DNA
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with pancreatic cancer through EUS-FNA. Exclusion Criteria: * Severe mental illness * Severe co-morbidity (ESRD, Advanced COPD, severe Heart failure, poorly controlled blood sugar) * Pregnancy * Patients who have received chemotherapy * Coagulopathy
References
Publications (0)
Data not yet available
No reference posted for this study.